'Cumulative hazard' presentation slideshows

Assume the model:

Borgan and Henderson: Event History Methodology Lancaster, September 2006 Session 2: Nelson-Aalen, Kaplan-Meier and Aalen-Johansen estimators. Nelson-Aalen estimator. Assume the model:. at risk indicator. common hazard/intensity (non-negative function).

668 views • 39 slides

Flexible Survival Modeling in SAS

507 views • 35 slides

The overwhelming case for LDL-C lowering

The overwhelming case for LDL-C lowering. Prof Kausik Ray, BSc ( hons ), MBChB , FRCP, MD, MPhil ( Cantab ), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary Consultant Cardiologist St Georges Hospital.

444 views • 27 slides

Fitting Cox regression models ALDA, Chapters Fourteen and Fifteen

368 views • 20 slides

Fitting Cox regression models ALDA, Chapters Fourteen and Fifteen

324 views • 20 slides

Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention

Statin Landmark Trials Across the Spectrum of Risk: Primary CV Prevention. Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial. Deaths/10,000 patient-years. 34. Increasing Risk. N = 316,099. 23. 21. 18. 17. 17. 12. 13. 11. 14.

345 views • 9 slides

General information on Project proposals received from Central Asia countries (required funds)

General information on Project proposals received from Central Asia countries (required funds). Cumulative hazard of radioactive waste in Central Asia. www . uranium . kg. Thank you for attention!.

187 views • 9 slides

Flow of Participants Through the Trial

Flow of Participants Through the Trial. IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445. Baseline Participant Characteristics. IDEAL Study - T.R. Pedersen, JAMA 2005; 294: 2437-2445. Baseline and Follow-up Levels of Lipids and Lipoproteins*.

201 views • 7 slides

Cumulative mortality post-MI in patients who use or no longer use snus (smokefree tobacco)

4. Cumulative mortality post-MI in patients who use or no longer use snus (smokefree tobacco). Post-MI Snus users. Post-MI Snus quitters. 3. 2. Cumulative hazard of mortality (%). 1. 0. 2. 1,5. 0. 0,5. 1. Arefalk et al., Circulation 2014.

127 views • 2 slides

DISCUSSION / CONCLUSIONS

Literature Data Survival Models: Case Studies for Anticoagulants in Atrial Fibrillation and Acute Coronary Syndrome Farkad Ezzet Pharsight, A Certara Company, St. Louis, MO, USA. INTRODUCTION. OBJECTIVE.

109 views • 1 slides